Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharmacoeconomic Evaluation of Long-term Effects on Health Recommended
October 11, 2004
- BUSINESS NEWS IN BRIEF
October 11, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 11, 2004
- Annual Business Results
October 11, 2004
- OTC NEWS IN BRIEF
October 11, 2004
- 1st Qtr Business Results
October 11, 2004
- MEDICAL DEVICE NEWS IN BRIEF
October 11, 2004
- Business Forecast
October 11, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 11, 2004
- PMDA to Increase Number, Quality of Reviewers: Mr Miyajima
October 11, 2004
- Drug Costs Increase 0.6 Points to 22.2% in FY2003: Korosho Survey
October 11, 2004
- Korosho Explains Key Points of GVP, GQP GLs
October 11, 2004
- Social Security Benefits Rose 2.7% to \83.5 Trillion in FY2002
October 11, 2004
- So-net M3 Sets Up Physicians' Job Change Site for Drug Houses
October 4, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 4, 2004
- REGULATORY NEWS IN BRIEF
October 4, 2004
- WORLD NEWS IN BRIEF
October 4, 2004
- BUSINESS NEWS IN BRIEF
October 4, 2004
- IITs Involve Insurance-related Problems
October 4, 2004
- NEW PRODUCTS
October 4, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…